P Rousselot

1.1k total citations
32 papers, 613 citations indexed

About

P Rousselot is a scholar working on Hematology, Genetics and Rheumatology. According to data from OpenAlex, P Rousselot has authored 32 papers receiving a total of 613 indexed citations (citations by other indexed papers that have themselves been cited), including 12 papers in Hematology, 11 papers in Genetics and 7 papers in Rheumatology. Recurrent topics in P Rousselot's work include Chronic Lymphocytic Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Eosinophilic Disorders and Syndromes (4 papers). P Rousselot is often cited by papers focused on Chronic Lymphocytic Leukemia Research (11 papers), Chronic Myeloid Leukemia Treatments (10 papers) and Eosinophilic Disorders and Syndromes (4 papers). P Rousselot collaborates with scholars based in France, United States and Germany. P Rousselot's co-authors include Corinne Alberti, Thierry Leblanc, Patricia Ribaud, Christophe Lacroix, Francis Derouin, Hagop M. Kantarjian, Neha Shah, Andreas Hochhaus, Yousif Matloub and Alexandre Lambert and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Journal of Hospital Infection.

In The Last Decade

P Rousselot

30 papers receiving 580 citations

Peers

P Rousselot

HEMAT

GENET

RHEUM

HTM

M. Michallet France

L Konopka Poland

Shigeru Oguma Japan

F. Brito‐Babapulle United Kingdom

Ingemar Winqvist Sweden

Judith A Collett New Zealand

Tetsu Oyama Japan

Lysiane Molina France

Fumihiko Monma Japan

Marco Montanaro Italy

M. Michallet France

P Rousselot

328 ×1.0

HEMAT

203 ×0.8

GENET

120 ×0.6

RHEUM

265 ×2.0

17 ×0.2

HTM

Citations per year, relative to P Rousselot P Rousselot (= 1×) peers M. Michallet

Countries citing papers authored by P Rousselot

Since Specialization

Citations

This map shows the geographic impact of P Rousselot's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by P Rousselot with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites P Rousselot more than expected).

Fields of papers citing papers by P Rousselot

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by P Rousselot. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by P Rousselot. The network helps show where P Rousselot may publish in the future.

Co-authorship network of co-authors of P Rousselot

This figure shows the co-authorship network connecting the top 25 collaborators of P Rousselot. A scholar is included among the top collaborators of P Rousselot based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with P Rousselot. P Rousselot is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Shah, Neha, D.-W. Kim, Hagop M. Kantarjian, et al.. (2010). Potent, transient inhibition of BCR-ABL with dasatinib 100 mg daily achieves rapid and durable cytogenetic responses and high transformation-free survival rates in chronic phase chronic myeloid leukemia patients with resistance, suboptimal response or intolerance to imatinib. Haematologica. 95(2). 232–240. 180 indexed citations

Shah, Neha, P Rousselot, Ricardo Pasqüini, et al.. (2006). Dasatinib (D) vs high dose imatinib (IM) in patients (pts) with chronic phase chronic myeloid leukemia (CP-CML) resistant to imatinib. Results of CA180017 START-R randomized trial. Journal of Clinical Oncology. 24(18_suppl). 6507–6507. 16 indexed citations

Shah, Neil P., Ricardo Pasqüini, P Rousselot, et al.. (2006). Dasatinib (SPRYCEL®) vs Escalated Dose of Imatinib (im) in Patients (pts) with Chronic Phase Chronic Myeloid Leukemia (CP-CML) Resistant to Imatinib: Results of the CA180-017 START-R Randomized Study.. Blood. 108(11). 167–167. 8 indexed citations

Hochhaus, Andreas, P Rousselot, P.E. Dorlhiac‐Llacer, et al.. (2006). Dasatinib (SPRYCEL®) 50mg or 70mg BID Versus 100mg or 140mg QD in Patients with Chronic Myeloid Leukemia in Chronic Phase (CML-CP) Resistant or Intolerant to Imatinib: Results of the CA180-034 Study.. Blood. 108(11). 166–166. 10 indexed citations

Cortes, Jörge E., D. W. Kim, Gianantonio Rosti, et al.. (2006). Dasatinib (D) in patients (pts) with chronic myelogenous leukemia (CML) in myeloid blast crisis (MBC) who are imatinib-resistant (IM-R) or IM-intolerant (IM-I): Results of the CA180006 ‘START-B’ study. Journal of Clinical Oncology. 24(18_suppl). 6529–6529. 16 indexed citations

Talpaz, Moshe, P Rousselot, François Guilhot, et al.. (2005). A Phase II Study of Dasatinib in Patients with Chronic Myeloid Leukemia (CML) in Myeloid Blast Crisis Who Are Resistant or Intolerant to Imatinib: First Results of the CA180006 ‘START-B’ Study.. Blood. 106(11). 40–40. 20 indexed citations

Tardieu, Sophie, P. Berthaud, Mauricette Michallet, et al.. (2004). Management of chronic myeloid leukemia in France: a multicentered cross-sectional study on 538 patients. Pharmacoepidemiology and Drug Safety. 14(8). 545–553. 24 indexed citations

Alberti, Corinne, Patricia Ribaud, Christophe Lacroix, et al.. (2001). Relationship between environmental fungal contamination and the incidence of invasive aspergillosis in haematology patients. Journal of Hospital Infection. 48(3). 198–206. 180 indexed citations

Rigau, Valérie, et al.. (2001). [HBME-1 immunostaining in thyroid pathology].. PubMed. 21(1). 15–20. 13 indexed citations

10.

Rousselot, P, H Rochant, Ali G. Turhan, et al.. (2000). Mise au point sur la leucémie myéloïde chronique. 6(2). 129–140.

11.

Morschhauser, F., JM Cayuela, Santi Martini, et al.. (2000). Evaluation of Minimal Residual Disease Using Reverse-Transcription Polymerase Chain Reaction in t(8;21) Acute Myeloid Leukemia: A Multicenter Study of 51 Patients. Journal of Clinical Oncology. 18(4). 788–788. 60 indexed citations

12.

Arsène, D, et al.. (1998). [Superficial cancer of the stomach in the area of Calvados from 1978 to 1990. Epidemiology and prognostic factors].. PubMed. 22(1). 6–12. 4 indexed citations

13.

André, Marc, Pauline Brice, Dominique Cazals, et al.. (1997). Results of three courses of adriamycin, bleomycin, vindesine, and dacarbazine with subtotal nodal irradiation in 189 patients with nodal Hodgkin’s disease (stage I, II and IIIA). PubMed. 39(2). 59–65. 15 indexed citations

14.

Fraitag, Sylvie, C. Bodemer, P Rousselot, et al.. (1995). [Cutaneous transformation of chronic lymphoid leukemia into immunoblastic lymphoma. Cutaneous manifestation of Richter syndrome].. PubMed. 122(8). 530–3. 8 indexed citations

15.

Leroy, D., et al.. (1984). [Reticulated and necrotic purpura (necrotic angiodermatitis type) due to arterial calcifications in chronic renal insufficiency].. PubMed. 111(5). 461–6. 1 indexed citations

16.

Borel, Benoît, et al.. (1982). [Visceral leishmaniasis. Anatomopathologic study apropos of a case with an epithelioid reaction].. PubMed. 30(4). 251–4. 1 indexed citations

17.

Rousselot, P, et al.. (1970). [Actinomycosis with thoraco-abdominal localization. A case in an 8-year-old child].. PubMed. 96(8). 563–8. 3 indexed citations

18.

L'hirondel, J, et al.. (1968). [Neonatal jaundice due to chlorpromazine].. PubMed. 25(10). 1171–7. 2 indexed citations

19.

Maleville, J, et al.. (1967). [Dysglobulinemic purpura and the Gougerot-Sjögren syndrome. Subsequent detection of a malignant reticulosis with a plasmacytic tendency].. PubMed. 74(5). 696–8. 3 indexed citations

20.

Bollack, C, et al.. (1966). [Apropos of a rare case of cavernous hemangioma of the bladder].. PubMed. 72(3). 171–5. 1 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact